Anti - agree with your sentiment on Celgene.
There an innovative Global Biotech that understands regenerative medicine and no doubt have been looking at MSB for months before deciding to take a stake.
Regarding TEVA, I share your frustration but post the appointment of Erez Vidogman ( Jan 2014 but on the Board since 2009 - nb: was there at the time of Teva / CEPH deal), in my view Teva's relationship with Meso has changed.
Recently Maxim Group's Jason Kolbert ( who follows both TEVA & MSB ) had this to say about the TEVA/MSB relationship:
...something very interesting about Mesoblast: Early on, it was partnered with Cephalon with its MPCs, but then Cephalon was acquired by Teva Pharmaceutical Industries. . .Teva then had to make a go or no-go decision on whether it would fund development of the MPCs. Over the last two years, Teva has been continuing to divest itself of R&D projects, yet one of the most prominent products that survived divestiture has been Mesoblast's Revascor. . .I believe that Teva and its new CEO, Erez Vigodman, and Michael Hayden, the head of R&D, now see the value that Revascor can deliver in CHF. I'm in the camp that believes it's going to work, but Mesoblast still has to prove efficacy in its current Phase 3, pivotal, global, double-blind trial with more than 1,700 patients. If the cells work, we're talking about a multibillion-dollar, druglike, blockbuster treatment." ..
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)